Company profile for NKGen Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in the immune-oncolo...
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in the immune-oncology space and are passionate and excited about the work we are doing to strengthen the immune system.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3001 Daimler St, Santa Ana, California 92705
Telephone
Telephone
949-396-6830
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/03/3198855/0/en/NKGen-Biotech-Inc-Issues-Statement-on-Recent-Board-Appointments-at-Majority-Owned-Korean-Affiliate-NKGen-Korea-Co-Ltd.html

GLOBENEWSWIRE
03 Dec 2025

https://www.globenewswire.com/news-release/2025/10/09/3164110/0/en/NKGen-Biotech-Provides-Clarification-on-Quotation-Display-and-Trading-Status-on-the-OTC-Expert-Market.html

GLOBENEWSWIRE
09 Oct 2025

https://www.globenewswire.com/news-release/2025/10/06/3161688/0/en/NKGen-Biotech-to-Present-on-the-Use-of-Troculeucel-for-Neurodegenerative-Diseases-at-the-XXVII-World-Congress-of-Neurology.html

GLOBENEWSWIRE
06 Oct 2025

https://www.globenewswire.com/news-release/2025/09/18/3152382/0/en/NKGen-Biotech-to-Present-on-the-Use-of-Troculeucel-for-Neurodegenerative-Diseases-at-the-3rd-China-Great-Bay-Cell-and-Gene-Therapy-Forum.html

GLOBENEWSWIRE
18 Sep 2025

https://www.globenewswire.com/news-release/2025/09/09/3146867/0/en/NKGen-Biotech-Inc-Announces-Completion-of-NKMax-Co-Ltd-Acquisition-Gains-Full-Control-of-Global-Manufacturing-and-Intellectual-Property-Assets.html

GLOBENEWSWIRE
09 Sep 2025

https://www.globenewswire.com/news-release/2025/08/06/3128258/0/en/NKGen-Biotech-To-Present-on-Allogeneic-Enhanced-NK-Cells-without-Lymphodepletion-in-Solid-Tumors-at-the-13th-Annual-Immuno-Oncology-Summit.html

GLOBENEWSWIRE
06 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty